- VTAK Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
DEFA14A Filing
Catheter Precision (VTAK) DEFA14AAdditional proxy soliciting materials
Filed: 23 Oct 20, 12:00am
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐ |
| Preliminary Proxy Statement |
☐ |
| Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) |
☐ |
| Definitive Proxy Statement |
☒ |
| Definitive Additional Materials |
☐ |
| Soliciting Material under §240.14a‑12 |
Ra Medical Systems, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
☒ | No fee required. |
☐ | Fee computed on table below per Exchange Act Rules 14a‑6(i)(1) and 0‑11. |
(1) |
| Title of each class of securities to which transaction applies:
|
|
|
|
(2) |
| Aggregate number of securities to which transaction applies:
|
|
|
|
(3) |
| Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0‑11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
|
(4) |
| Proposed maximum aggregate value of transaction:
|
|
|
|
(5) |
| Total fee paid:
|
☐ | Fee paid previously with preliminary materials. |
☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0‑11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement |
(1) |
| Amount Previously Paid:
|
|
|
|
(2) |
| Form, Schedule or Registration Statement No.:
|
|
|
|
(3) |
| Filing Party:
|
|
|
|
(4) |
| Date Filed:
|
On September 2, 2020, Ra Medical Systems, Inc. (the “Company”) commenced distributing to its stockholders a Notice of Annual Meeting of Stockholders and Definitive Proxy Statement (the “Notice and Proxy Statement”) for its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on October 12, 2020. A copy of the Notice and Proxy Statement was filed with the Securities and Exchange Commission on August 28, 2020. On October 12, 2020 the Annual Meeting was adjourned prior to voting on Proposal 3 to allow additional time for voting. As announced during the Annual Meeting, the Annual Meeting is to reconvene at 9:00 a.m. Pacific Time on November 2, 2020. On October 15, 2020, the Company (i) mailed a letter to certain of its stockholders (the “ First Letter”), and (ii) commenced disseminating an audio recording (the “Recording”) to certain of its stockholders by telephone, in each case related to Proposal 3, which proposal is described in the Notice and Proxy Statement. On October 19, 2020, the Company mailed a postcard to certain of its stockholders related to Proposal 3 (the “Postcard”), which proposal is described in the Notice and Proxy Statement. On October 22, 2020, the Company mailed a letter to certain of its stockholders to certain of its stockholders related to Proposal 3 (the “Second Letter”), which proposal is described in the Notice and Proxy Statement.
200 Broadacres Drive, 3rd Floor |
IMPORTANT REMINDER TO VOTE
October 22, 2020
Dear Ra Medical Systems Stockholder:
The Annual Meeting has been adjourned to November 2, 2020 with respect to proposal 3 seeking approval to effect a reverse stock split.
The reverse split is intended to:
| ➢ | Increase the per share trading price to satisfy the $1.00 minimum bid price requirement to remain on the NYSE |
| ➢ | Provide a broader market with more trading volume by maintaining our NYSE listing which we believe will help generate more interest among investors |
What happens if the reverse split is NOT approved?
| ➢ | Failure to meet the $1.00 minimum bid price requirement will result in delisting from the NYSE after December 31, 2020 |
| ➢ | Delisting could result in additional challenges to raise capital in the future as well as reduced trading liquidity for the stock |
Please take a moment to vote by calling toll-free 833-945-2699. Representatives are available Monday through Friday 9 a.m. to 10 p.m. EST.
Sincerely,
Melissa Carlson
Vice President
VOTE TODAY
CALL TOLL – FREE
(833) 945 - 2699
The Shareholder Communication Strategists
Copyright © 2020 by Alliance Advisors, LLC. ALL RIGHTS RESERVED